In the latest trading session, 0.46 million IN8bio Inc (NASDAQ:INAB) shares changed hands as the company’s beta touched -0.01. With the company’s most recent per share price at $0.32 changing hands around $0.0 or 0.00% at last look, the market valuation stands at $22.98M. INAB’s current price is a discount, trading about -443.75% off its 52-week high of $1.74. The share price had its 52-week low at $0.22, which suggests the last value was 31.25% up since then. When we look at IN8bio Inc’s average trading volume, we note the 10-day average is 1.13 million shares, with the 3-month average coming to 1.39 million.
Analysts gave the IN8bio Inc (INAB) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.40. If we narrow down to specifics, the data shows that 0 out of 2 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended INAB as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight. IN8bio Inc’s EPS for the current quarter is expected to be -0.08.
IN8bio Inc (NASDAQ:INAB) trade information
The company’s shares are showing year-to-date upside of 23.25%, with the 5-day performance at -8.91% in the red. However, in the 30-day time frame, IN8bio Inc (NASDAQ:INAB) is -1.28% down. Looking at the short shares, we see there were 1.0 million shares sold at short interest cover period of 0.51 days.
IN8bio Inc (INAB) estimates and forecasts
Data shows that the IN8bio Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -62.66% over the past 6 months, a 44.00% in annual growth rate that is considerably higher than the industry average of 16.70%.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -50.62%. The 2025 estimates are for IN8bio Inc earnings to increase by 43.67%.
INAB Dividends
IN8bio Inc is expected to release its next quarterly earnings report in February.
IN8bio Inc (NASDAQ:INAB)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 21.56% of IN8bio Inc shares while 46.46% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 59.23%. There are 46.46% institutions holding the IN8bio Inc stock share, with AIGH CAPITAL MANAGEMENT LLC the top institutional holder. As of 2024-06-30, the company held 4.9157% of the shares, roughly 2.13 million INAB shares worth $1.8 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 3.2892% or 1.42 million shares worth $1.21 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. With 952.49 shares estimated at $0.31 million under it, the former controlled 1.31% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 0.65% of the shares, roughly 471.41 shares worth around $0.15 million.
